Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
52 hedge funds and large institutions have $196M invested in Adamas Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 7 reducing their positions, and 6 closing their positions.
208% more capital invested
Capital invested by funds: $63.7M → $196M (+$133M)
200% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 7
150% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 6
18% more funds holding
Funds holding: 44 → 52 (+8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.11M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.75M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.59M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$1.34M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$1.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BS
Bow Street
New York
|
-$1.65M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$1.46M |
| 3 |
BG
BlackRock Group
London,
United Kingdom
|
-$890K |
| 4 |
BlackRock
New York
|
-$393K |
| 5 |
D.E. Shaw & Co
New York
|
-$241K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $2K | +$1.52K | +100 | New |
|
|
BS
52
Bow Street
New York
| – | -$1.65M | -88,560 | Closed |
|
|
BG
53
BlackRock Group
London,
United Kingdom
| – | -$890K | -47,800 | Closed |
|
|
54
BlackRock
New York
| – | -$393K | -21,100 | Closed |
|
|
55
D.E. Shaw & Co
New York
| – | -$241K | -12,969 | Closed |
|
56
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$14 | -732 | Closed |
|
57
BNP Paribas Financial Markets
Paris,
France
| – | -$1.71K | -92 | Closed |
|
58
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$197 | +13 | New |
|
ADMS Hedge Fund Activity: Q4 2014 in Review
52 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q4 2014, worth a combined $196M — up 208% from $63.7M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ADMS positions and 6 closed out — a net gain of 9 holders — while 21 added to existing stakes and 7 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $7.11M. The largest seller was Bow Street, exiting entirely with an estimated $1.65M sold.
- 52 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q4 2014, up from 44 in Q3 2014.
- Funds reported $196M of Adamas Pharmaceuticals stock for Q4 2014, up 208% quarter-over-quarter.
- 15 funds opened new Adamas Pharmaceuticals positions in Q4 2014 and 6 closed out, a net change of +9 holders.
- The largest Adamas Pharmaceuticals buyer in Q4 2014 was Fidelity Investments, an estimated $7.11M added.
- The largest Adamas Pharmaceuticals seller in Q4 2014 was Bow Street, an estimated $1.65M sold.
Based on aggregated 13F filings for Q4 2014.